Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever

Basit Öğe Kaydı
dc.authoridSAHIN, ALI/0000-0002-6953-4276
dc.authoridAlbayrak, Fatih/0000-0002-6052-3896
dc.contributor.authorSahin, Ali
dc.contributor.authorDerin, Mehmet Emin
dc.contributor.authorAlbayrak, Fatih
dc.contributor.authorKarakas, Burak
dc.contributor.authorKaragoz, Yalcin
dc.date.accessioned2024-10-26T18:05:42Z
dc.date.available2024-10-26T18:05:42Z
dc.date.issued2020
dc.departmentSivas Cumhuriyet Üniversitesi
dc.description.abstractIntroduction: Familial Mediterranean fever (FMF) is a hereditary auto-inflammatory disease characterized by recurrent fever and serosal inflammation. Anti-interleukin-1 (Anti-IL-1) treatments are recommended in colchicine resistant and/or intolerant FMF patients. This study aims to evaluate the efficacy of anakinra and canakinumab in FMF patients that are resistant/intolareted to colchicine or complicated with amyloidosis. Methods: Between January 2014 and March 2019, 65 patients following-up at Sivas Cumhuriyet University (Medical Faculty Rheumatology-Internal Medicine Department) who were diagnosed with FMF according to the criteria of Tel-Hashomer were included in the study. The laboratory values and clinical features of patients and disease activities were recorded at least every 3 months, and these data were analyzed. Results: Forty-one (63.1%) patients used anakinra (100 mg/day) and 24 (36.9%) patients used canakinumab (150 mg/8 week). The median duration of anti-IL-1 agents use was 7 months (range, 3-30). Fifteen (23.1%) cases were complicated with amyloidosis. Seven (10.8%) patients had renal transplantation. Overall, the FMF 50 score response was 96.9%. In the group that had a glomerular filtration rate (GFR) >= 60 ml/min/m(2), the median proteinuria decreased from 2390 mg/day (range, 14007200) to 890 mg/day (range, 1202750) (p = 0.008). No serious infections were detected, except in one patient. Conclusions: Anti-IL-1 agents are effective and safe in the treatment of FMF patients. These agents are particularly effective at reducing proteinuria in patients with GFR >= 60 ml/min/m(2), but less effective in cases with FMF associated with arthritis and sacroiliitis. Large and long follow-up studies are now needed to establish the longterm effects of these treatments.
dc.identifier.doi10.1186/s42358-020-0117-1
dc.identifier.issn2523-3106
dc.identifier.issue1
dc.identifier.pmid32000860
dc.identifier.scopus2-s2.0-85078710059
dc.identifier.scopusqualityQ3
dc.identifier.urihttps://doi.org/10.1186/s42358-020-0117-1
dc.identifier.urihttps://hdl.handle.net/20.500.12418/29145
dc.identifier.volume60
dc.identifier.wosWOS:000513248200001
dc.identifier.wosqualityQ4
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherBmc
dc.relation.ispartofAdvances in Rheumatology
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectAnakinra
dc.subjectCanakinumab
dc.subjectFamilial Mediterranean fever (FMF)
dc.subjectAmyloidosis
dc.subjectColchicine-resistant
dc.titleAssessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
dc.typeArticle

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksyonu
Scopus İndeksli Yayınlar Koleksiyonu